Reading MPLT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MPLT free→Reading MPLT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MPLT free→QuarterlyIQ Insights · MPLT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Chief Financial Officer — Vishwas Setia: Mr. Setia was separated as CFO following a review of a human resources violation.
Results of Operations and Financial Condition. On May 14, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Excha…
Director — Robert Malenka, Jim Trenkle: Dr. Malenka and Dr. Trenkle decided not to stand for reelection, with successors already nominated.
Results of Operations and Financial Condition. On March 26, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of…
Results of Operations and Financial Condition. On January 9, 2026, MapLight Therapeutics, Inc. (the "Company") released the Presentation (as defined below), which includes the following selected preliminary financial information for the fiscal year ended December 31, 2025: As of December 31, 2025, the Company's cash and cash equivalents were approximately $450 million. The cash and cash equivalents information above and in the Presentation is preliminary, has not been audited and is subject t…
Results of Operations and Financial Condition. On December 4, 2025, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securiti…
Other Events. On October 26, 2025, the Company entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), in connection with the IPO, for the issuance and sale by the Company of 14,750,000 shares of Common Stock, at an initial public offering price of $17.00 per share, le…
Unregistered Sales of Equity Securities. The disclosure set forth below under
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.